In Phase C, individuals will obtain ABBV-744 and oral navitoclax. In Section D, individuals will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally condition progression or perhaps the individuals are not able to tolerate the study drugs. Celastrol was identified to be a Myb inhibitor that suppressed C/EBPβ https://abbv-744-cancer-treatment02468.blogs100.com/32398879/abbv-744-in-combination-with-immunotherapy-an-overview